- Achievement increases total production capacity available to serve international medical markets by 230%
- Brings Aurora’s total number of EU GMP certified Canadian production facilities to 3
- Pharmacies in Germany have been instructed to resume sales of Aurora’s suite of medical cannabis following temporary pause
NYSE | TSX : ACB
EDMONTON , Feb. 3, 2020 /CNW/ – Aurora Cannabis Inc. (“Aurora” or the “Company”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, announced today its Aurora River production facility, located in Bradford, Ontario , has received European Union Good Manufacturing Practice (“EU GMP”) certification. EU GMP certification is granted to companies whose production facilities demonstrate a high degree of quality and consistency in their manufacturing procedures and is a requirement for the export of medical cannabis products into most European markets.
In addition, Aurora is pleased to announce it has received all necessary approvals from local regulators in Germany for sales of its medical cannabis products, following a temporary sales suspension on certain products in December 2019 . Aurora will fulfill existing sales orders from inventory currently held in Germany , ensuring local patients will have immediate access to medicine from their preferred pharmacy.
Read The Full Article: Aurora Cannabis Receives EU GMP Certification for its Aurora River Facility